LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset (ID:20238)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Ruxolitinib | 0.12 | uM | LJP5 | 3 | O17 | 72 | hr | 2543 | 5572 | 5578 | 0.9988 | 0.9978 |
| SK-BR-3 | XL147 | 0.12 | uM | LJP5 | 1 | G11 | 72 | hr | 2543 | 6012 | 5578 | 1.0777 | 1.1428 |
| SK-BR-3 | XL147 | 0.12 | uM | LJP5 | 2 | G11 | 72 | hr | 2543 | 6028 | 5578 | 1.0805 | 1.1480 |
| SK-BR-3 | XL147 | 0.12 | uM | LJP5 | 3 | G11 | 72 | hr | 2543 | 5690 | 5578 | 1.0200 | 1.0367 |
| SK-BR-3 | Saracatinib | 0.12 | uM | LJP6 | 1 | D11 | 72 | hr | 2543 | 5468 | 5578 | 0.9802 | 0.9635 |
| SK-BR-3 | Saracatinib | 0.12 | uM | LJP6 | 2 | D11 | 72 | hr | 2543 | 5370 | 5578 | 0.9626 | 0.9313 |
| SK-BR-3 | Saracatinib | 0.12 | uM | LJP6 | 3 | D11 | 72 | hr | 2543 | 5552 | 5578 | 0.9952 | 0.9912 |
| SK-BR-3 | Selumetinib | 0.12 | uM | LJP6 | 1 | M11 | 72 | hr | 2543 | 5575 | 5578 | 0.9993 | 0.9988 |
| SK-BR-3 | Selumetinib | 0.12 | uM | LJP6 | 2 | M11 | 72 | hr | 2543 | 5389 | 5578 | 0.9660 | 0.9375 |
| SK-BR-3 | Selumetinib | 0.12 | uM | LJP6 | 3 | M11 | 72 | hr | 2543 | 5514 | 5578 | 0.9884 | 0.9787 |
| SK-BR-3 | Sirolimus | 0.12 | uM | LJP6 | 1 | L17 | 72 | hr | 2543 | 3543 | 5578 | 0.6351 | 0.3293 |
| SK-BR-3 | Sirolimus | 0.12 | uM | LJP6 | 2 | L17 | 72 | hr | 2543 | 3687 | 5578 | 0.6609 | 0.3768 |
| SK-BR-3 | Sirolimus | 0.12 | uM | LJP6 | 3 | L17 | 72 | hr | 2543 | 3827 | 5578 | 0.6860 | 0.4229 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 1 | B11 | 72 | hr | 2543 | 5463 | 5578 | 0.9793 | 0.9619 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 2 | B11 | 72 | hr | 2543 | 5644 | 5578 | 1.0117 | 1.0215 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 3 | B11 | 72 | hr | 2543 | 5501 | 5578 | 0.9861 | 0.9744 |
| SK-BR-3 | SU11274 | 0.12 | uM | LJP5 | 1 | J11 | 72 | hr | 2543 | 5827 | 5578 | 1.0445 | 1.0818 |
| SK-BR-3 | SU11274 | 0.12 | uM | LJP5 | 2 | J11 | 72 | hr | 2543 | 5990 | 5578 | 1.0737 | 1.1355 |
| SK-BR-3 | SU11274 | 0.12 | uM | LJP5 | 3 | J11 | 72 | hr | 2543 | 6173 | 5578 | 1.1065 | 1.1958 |
| SK-BR-3 | Fedratinib | 0.12 | uM | LJP5 | 1 | L05 | 72 | hr | 2543 | 5741 | 5578 | 1.0291 | 1.0535 |
| SK-BR-3 | Fedratinib | 0.12 | uM | LJP5 | 2 | L05 | 72 | hr | 2543 | 5422 | 5578 | 0.9719 | 0.9484 |
| SK-BR-3 | Fedratinib | 0.12 | uM | LJP5 | 3 | L05 | 72 | hr | 2543 | 5952 | 5578 | 1.0669 | 1.1230 |
| SK-BR-3 | TGX221 | 0.12 | uM | LJP5 | 1 | H23 | 72 | hr | 2543 | 5034 | 5578 | 0.9024 | 0.8206 |
| SK-BR-3 | TGX221 | 0.12 | uM | LJP5 | 2 | H23 | 72 | hr | 2543 | 4824 | 5578 | 0.8647 | 0.7514 |
| SK-BR-3 | TGX221 | 0.12 | uM | LJP5 | 3 | H23 | 72 | hr | 2543 | 5198 | 5578 | 0.9318 | 0.8746 |